CNC

CNC

USD

Centene Corporation Common Stock

$57.690-0.710 (-1.216%)

Reaalajas hind

Healthcare
Healthcare Plans
Ameerika Ühendriigid

Hinnagraafik

Põhinäitajad

Turunäitajad
Ettevõtte fundamentaalnäitajad
Kauplemisstatistika

Turunäitajad

Avatud

$58.400

Kõrge

$58.870

Madal

$56.060

Maht

0.94M

Ettevõtte fundamentaalnäitajad

Turukapitalisatsioon

30.5B

Tööstusharu

Healthcare Plans

Riik

United States

Kauplemisstatistika

Keskmine maht

4.81M

Börs

NYQ

Valuuta

USD

52 nädala vahemik

Madal $55.03Praegune $57.690Kõrge $80.59

Tehisintellekti analüüsiaruanne

Viimati uuendatud: 24. apr 2025
Tehisintellekti loodudAndmeallikas: Yahoo Finance, Bloomberg, SEC

CNC: Centene Corporation Common Stock - What's Happening and What to Watch

Stock Symbol: CNC Generate Date: 2025-04-24 23:56:23

Alright, let's break down what's been going on with Centene (CNC) lately. Think of this as catching up on the company's story and figuring out what the next chapter might look like, based on the latest info.

Recent News Buzz: What's the Vibe?

Looking at the news from the past few weeks, the overall feeling around Centene seems pretty positive, maybe even leaning bullish. Why? A few things stand out.

First off, their subsidiary, Health Net, has been busy. They're partnering up to improve patient care in Sacramento, giving out a big grant ($3.5 million!) to add doctors in Los Angeles, and even committing $1 million to help rebuild after a fire. This kind of community involvement and partnership news is generally seen as a good sign – it shows the company is active and investing in its service areas.

Then there's the business side. Centene's SilverSummit Healthplan just landed a Nevada Medicaid contract. Winning contracts like this is a direct boost to their core business, showing they're competitive and growing their reach.

On top of that, the whole health insurance sector got a lift recently. The government announced better-than-expected payment rates for Medicare Advantage plans for 2026. Since Centene is a big player in Medicare, this is definitely good news for them.

Analyst opinions have been a bit mixed, but with a positive tilt. While one analyst lowered their price target slightly (though kept a 'Neutral' rating), another initiated coverage with 'Neutral', and importantly, Jefferies upgraded the stock from 'Underperform' to 'Hold' and gave it a significantly higher price target. An upgrade and a raised target usually catch investors' eyes.

So, summing up the news: lots of positive activity on the ground, a key contract win, favorable sector news, and some encouraging signs from analysts. That paints a generally optimistic picture.

Price Check: What Has the Stock Been Doing?

Now, let's look at the stock price itself over the last few months. It's been a bit of a ride. Back in late January, shares were trading in the mid-$60s. Then, they took a noticeable dip in early February, dropping into the mid-to-high $50s. For most of February and March, the price bounced around in that $57 to $61 range – kind of trading sideways after the fall.

Things got more interesting in early April. The stock saw a pretty sharp jump around April 3rd, pushing it up towards the mid-$60s again. Since that jump, it's been a bit volatile, pulling back some but still holding above the levels seen in February and March.

As of today, April 24th, the stock closed around $61.58. The AI prediction for today was a slight dip, which fits with the close being a little below the open. Looking ahead, the AI model predicts a small rise tomorrow (around 0.93%) followed by another slight dip the day after. So, the AI sees a little bounce coming up very soon.

Putting It Together: Outlook & Ideas

Considering the positive news flow – especially the contract win and the good sector news on Medicare rates – combined with the stock's recovery from its earlier dip and the AI's prediction for a near-term uptick, the situation seems to lean cautiously positive right now. It doesn't scream "buy everything immediately," but it certainly doesn't suggest running for the hills either.

Based on this, a 'hold' position makes sense if you're already in. If you're thinking about getting in, or adding more, the current price area around $61.50-$62.00 could be a point to consider. Why this level? It's where the stock is trading now, and the AI predicts a small rise from here tomorrow. Plus, the recommendation data points to potential entry levels right around here ($61.73, $62.01) and notes support near $61.88. Entering near support or current levels, especially if the AI bounce prediction holds, could be one strategy.

What about managing risk? The recommendation data suggests a stop-loss around $55.90. This level is just above the stock's 52-week low and below the recent trading range, so if the price drops below this point, it could signal a breakdown in the current trend, and cutting losses might be wise. For taking profits, the data suggests $65.66. This is below the recent high but represents a decent gain from current levels if the positive momentum continues.

Company Context Snapshot

Just remember, Centene is a giant in the healthcare space, heavily focused on government programs like Medicaid and Medicare. That's why news about contract wins in those areas and changes to Medicare payment rates are really important drivers for their business and, consequently, their stock price. While they have a relatively low P/E ratio compared to their industry peers, which can sometimes signal value, it's also worth noting from the recommendation data that their debt is on the higher side and revenue growth has been modest. These are factors to keep in mind for the longer term, but the recent news and price action are more about the near-term picture.


Disclaimer: This analysis is based on the provided data and is for informational purposes only. It is not financial advice. Stock markets are volatile, and prices can go down as well as up. Always do your own thorough research or consult with a qualified financial advisor before making any investment decisions.

Seotud uudised

PR Newswire

CENTENE CORPORATION REPORTS FIRST QUARTER 2025 RESULTS

Centene Corporation (NYSE: CNC) (the Company) announced today its financial results for the first quarter ended March 31, 2025. In summary, the 2025...

Vaata rohkem
CENTENE CORPORATION REPORTS FIRST QUARTER 2025 RESULTS
PR Newswire

Health Net, Dignity Health and Vivant Health Partner to Improve Patient Care in Sacramento Hospitals

A groundbreaking collaboration between Health Net (a Centene Corporation company), Dignity Health (a CommonSpirit Health member) and Vivant Health...

Vaata rohkem
Health Net, Dignity Health and Vivant Health Partner to Improve Patient Care in Sacramento Hospitals
CNBC

Healthy Returns: Trump seeks to change Medicare drug price negotiations in a win for pharma

Trump proposed a change to Medicare price talks that has long been sought after by the pharmaceutical industry.

Vaata rohkem
Healthy Returns: Trump seeks to change Medicare drug price negotiations in a win for pharma
PR Newswire

MLK Community Medical Group Adds Two Primary Care Doctors, One OB/GYN and Three Other Clinical Staff Thanks to $3.5 Million Grant from Health Net

Health Net, one of California's most experienced Medi-Cal managed care health plans and a company of Centene Corporation (NYSE: CNC), today announced ...

Vaata rohkem
MLK Community Medical Group Adds Two Primary Care Doctors, One OB/GYN and Three Other Clinical Staff Thanks to $3.5 Million Grant from Health Net
PR Newswire

Health Net and Centene Foundation Commit $1 Million to Rebuild Los Angeles After Historic Fire Devastation

One hundred days after the devastating Eaton Fire began, Health Net, one of California's most experienced Medi-Cal managed care health plans, and the ...

Vaata rohkem
Health Net and Centene Foundation Commit $1 Million to Rebuild Los Angeles After Historic Fire Devastation
Analyst Upgrades

Baird Maintains Neutral on Centene, Lowers Price Target to $69

Baird analyst Michael Ha maintains Centene with a Neutral and lowers the price target from $71 to $69.

PR Newswire

CENTENE SUBSIDIARY SILVERSUMMIT HEALTHPLAN AWARDED NEVADA MEDICAID CONTRACT

Centene Corporation (NYSE: CNC), a leading healthcare enterprise committed to helping people live healthier lives, announced today that its Nevada...

Tehisintellekti ennustusBeta

Tehisintellekti soovitus

Langev

Uuendatud kell: 28. apr 2025, 03:20

LangevNeutraalneTõusev

64.5% Kindlus

Risk ja kauplemine

Riskitase1/5
Madal risk
Sobib
VäärtusKonservatiivne
Kauplemisjuhend

Sisenemispunkt

$57.33

Võta kasum

$58.84

Peata kahjum

$55.15

Põhitegurid

PDI 8.6 on MDI 6.2 kohal ADX-iga 11.0, mis viitab tõusutrendile
Praegune hind on tugitasemele ($57.50) äärmiselt lähedal, mis viitab tugevale ostuvõimalusele
Kauplemismaht on 12.7x keskmisest (46,431), mis viitab äärmiselt tugevale ostusurvele
MACD 0.0236 on signaalijoone -0.0106 kohal, mis viitab tõusvale ristumisele

Püsi kursis

Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.